Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

New Psychoactive Substances, New Behaviours, New Drug-drug Interactions: Pharmacology of a Slam Session

Author(s): Benoit Schreck, Marion Istvan, Marylène Guerlais, Edouard-Jules Laforgue, Marie Gérardin, Marie Grall-Bronnec, Aurélie Aquizerate and Caroline Victorri-Vigneau*

Volume 24, Issue 2, 2023

Published on: 17 March, 2023

Page: [80 - 91] Pages: 12

DOI: 10.2174/1389200224666230228103922

Price: $65

Abstract

Background: Slamming has been increasing internationally for ten years, mostly among men who have sex with men. Slamming consists of injecting psychostimulants (including new psychoactive substances-NPS) intravenously to increase sexual performance.

Objective: The objective of our work was to analyse drug-drug interactions related to slamming.

Methods: Drawing upon a reported case of a slam session describing hour by hour the intake of substances, we performed a drug-interaction analysis using international references and a comprehensive literature review. High doses of sildenafil, GBL and 3-MMC were reported during the 40-hour session described. The specific drug-interaction research was performed using 9 references and 65 of the 209 records identified in the literature review.

Results: Pharmacological data regarding nonmedicated substances were scarce. Regarding pharmacodynamics, the risk was high at the cardiovascular level and was related to the vasodilatation effect of sildenafil and the adrenergic and serotoninergic properties of stimulants; this risk may increase with usual treatment (involving other vasodilators or central depressants). Regarding pharmacokinetics, the major interactions concerned metabolism by CYP3A4 and CYP2C9, leading to interactions, particularly with HIV medication.

Conclusion: This innovative work provides pharmacological information on drugs that are commonly used in slamming, allowing the development of effective medical-management protocols and the provision of risk-reduction counselling.

« Previous
Graphical Abstract

[1]
EU Drug Markets Report 2019;; Publications Office of the European Union.: Luxembourg, 2019.
[2]
European drug report 2021: trends and developments; Publications Office of the European Union: Luxembourg, 2021.
[3]
Martinez, M.; Néfau, T.; Cadet-Taïrou, A. New synthetic products-ten years of hindsight on the french situation. Paris: French observatoryof drugs and drug addiction. 2018. Available from: https://www.ofdt.fr/BDD/publications/docs/eftxmmya.pdf (accessed February 17, 2022).
[4]
Riley, A.L.; Nelson, K.H.; To, P.; López-Arnau, R.; Xu, P.; Wang, D.; Wang, Y.; Shen, H.; Kuhn, D.M.; Angoa-Perez, M.; Anneken, J.H.; Muskiewicz, D.; Hall, F.S. Abuse potential and toxicity of the synthetic cathinones (i.e., “Bath salts”). Neurosci. Biobehav. Rev., 2020, 110, 150-173.
[http://dx.doi.org/10.1016/j.neubiorev.2018.07.015] [PMID: 31101438]
[5]
Schifano, F.; Napoletano, F.; Arillotta, D.; Zangani, C.; Gilgar, L.; Guirguis, A.; Corkery, J.M.; Vento, A. The clinical challenges of synthetic cathinones. Br. J. Clin. Pharmacol., 2020, 86(3), 410-419.
[http://dx.doi.org/10.1111/bcp.14132] [PMID: 31674690]
[6]
Valente, M.J.; Guedes de Pinho, P.; de Lourdes Bastos, M.; Carvalho, F.; Carvalho, M. Khat and synthetic cathinones: A review. Arch. Toxicol., 2014, 88(1), 15-45.
[http://dx.doi.org/10.1007/s00204-013-1163-9] [PMID: 24317389]
[7]
Prosser, J.M.; Nelson, L.S. The toxicology of bath salts: A review of synthetic cathinones. J. Med. Toxicol., 2012, 8(1), 33-42.
[http://dx.doi.org/10.1007/s13181-011-0193-z] [PMID: 22108839]
[8]
Gaissad, L.; Velter, A. “Getting high to get laid.” Drugs and gay sex under influence. Sexologies, 2019, 28(3), e48-e53.
[http://dx.doi.org/10.1016/j.sexol.2019.06.007]
[9]
Le Talec, J.Y.; Linard, F. Plaisirs chimiques: sexualité et usage de drogues chez des hommes gais séropositifs. Psychotr. (Paris), 2015, 21(2), 157-182.
[http://dx.doi.org/10.3917/psyt.212.0157]
[10]
Fournier, S; Escots, S Male homosexuality and use of psychoactive substances in gay festive contexts. French observatory for drugs and drug addiction. 2010. Available from: http://www.ofdt.fr/BDD/publications/docs/epfxsfq9.pdf (accessed February 17, 2022)
[11]
Broqua, C.; Lert, F.; Souteyrand, Y. Homosexualities in the time of AIDS: social and identity tensions. , 2003. Available from: https://www.researchgate.net/publication/271587097_Homosexualites_au_temps_du_sida_tensions_sociales_et_identitaires (accessed February 17, 2022)
[12]
Bourne, A.; Reid, D.; Hickson, F.; Torres Rueda, S.; Weatherburn, P. The Chemsex study: Drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham; , 2014. Available From: http://researchonline.lshtm.ac.uk/2197245/
[13]
Deimel, D.; Stöver, H.; Hößelbarth, S.; Dichtl, A.; Graf, N.; Gebhardt, V. Drug use and health behaviour among German men who have sex with men: Results of a qualitative, multi-centre study. Harm. Reduct. J., 2016, 13(1), 36.
[http://dx.doi.org/10.1186/s12954-016-0125-y] [PMID: 27938393]
[14]
Bourne, A.; Ong, J.; Pakianathan, M. Sharing solutions for a reasoned and evidence-based response: chemsex/party and play among gay and bisexual men. Sex. Health, 2018, 15(2), 99-101.
[http://dx.doi.org/10.1071/SH18023] [PMID: 29754596]
[15]
Giraudon, I.; Schmidt, A.J.; Mohammed, H. Surveillance of sexualised drug use - the challenges and the opportunities. Int. J. Drug Policy, 2018, 55, 149-154.
[http://dx.doi.org/10.1016/j.drugpo.2018.03.017] [PMID: 29598967]
[16]
Gilbart, V.L.; Simms, I.; Jenkins, C.; Furegato, M.; Gobin, M.; Oliver, I.; Hart, G.; Gill, O.N.; Hughes, G. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales: Table 1. Sex. Transm. Infect., 2015, 91(8), 598-602.
[http://dx.doi.org/10.1136/sextrans-2015-052014] [PMID: 25921020]
[17]
Batisse, A.; Fortias, M.; Bourgogne, E.; Grégoire, M.; Sec, I.; Djezzar, S. Case series of 21 synthetic cathinones abuse. J. Clin. Psychopharmacol., 2014, 34(3), 411-413.
[http://dx.doi.org/10.1097/JCP.0000000000000116] [PMID: 24743721]
[18]
Weatherburn, P.; Hickson, F.; Reid, D.; Torres-Rueda, S.; Bourne, A. Motivations and values associated with combining sex and illicit drugs (‘chemsex’) among gay men in South London: findings from a qualitative study. Sex. Transm. Infect., 2017, 93(3), 203-206.
[http://dx.doi.org/10.1136/sextrans-2016-052695] [PMID: 27519259]
[19]
Schreck, B.; Victorri-Vigneau, C.; Guerlais, M.; Laforgue, E.; Grall-Bronnec, M. Slam practice: A review of the literature. Eur. Addict. Res., 2021, 27(3), 161-178.
[http://dx.doi.org/10.1159/000511897] [PMID: 33279895]
[20]
Edmundson, C.; Heinsbroek, E.; Glass, R.; Hope, V.; Mohammed, H.; White, M.; Desai, M. Sexualised drug use in the United Kingdom (UK): A review of the literature. Int. J. Drug Policy, 2018, 55, 131-148.
[http://dx.doi.org/10.1016/j.drugpo.2018.02.002] [PMID: 29625796]
[21]
Schreck, B.; Guerlais, M.; Laforgue, E.; Bichon, C.; Grall-Bronnec, M.; Victorri-Vigneau, C. Cathinone use disorder in the context of slam practice: New pharmacological and clinical challenges. Front. Psychiatry, 2020, 11, 705.
[http://dx.doi.org/10.3389/fpsyt.2020.00705] [PMID: 32792999]
[22]
Barberot, P.; Gibaja, V.; Benkhedda, C.; Dobre, D.; Tournebize, J.; Kahn, J.P. Identification of cases of abuse/dependency by the French addictovigilance network: a pilot study by CEIP-A and the Center psychothérapique de Nancy. Therapie, 2019, 74(3), 389-397.
[http://dx.doi.org/10.1016/j.therap.2018.10.002] [PMID: 30392700]
[23]
Code de la santé publique - Article R5132-113. Available From: https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000034687202/2017-05-11
[24]
Code de la santé publique - Article R5132-114. Available From: https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000034687195
[25]
The french public drug product database. Base de données publiquedes médicaments 2022 Available From: https://base-donnees-publique.medicaments.gouv.fr/ (accessed February 17, 2022)
[26]
The Food & Drug Administration. FDA-Approuved Drugs - U.S. Food & Drug Administration. , 2022. Available From: https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed February 17, 2022)
[27]
Wishart, D.S.; Feunang, Y.D.; Guo, A.C.; Lo, E.J.; Marcu, A.; Grant, J.R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; Assempour, N.; Iynkkaran, I.; Liu, Y.; Maciejewski, A.; Gale, N.; Wilson, A.; Chin, L.; Cummings, R.; Le, D.; Pon, A.; Knox, C.; Wilson, M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res., 2018, 46(D1), D1074-D1082.
[http://dx.doi.org/10.1093/nar/gkx1037] [PMID: 29126136]
[28]
DrugBank. Available from: https://go.drugbank.com/
[29]
Banerjee, P.; Dunkel, M.; Kemmler, E.; Preissner, R. SuperCYPsPred-a web server for the prediction of cytochrome activity. Nucleic Acids Res., 2020, 48(W1), W580-W585.
[http://dx.doi.org/10.1093/nar/gkaa166] [PMID: 32182358]
[30]
SuperCYPsPred. Available From: http://insilico-cyp.charite.de/SuperCYPsPred/index.php?site=Statistics (accessed February 7, 2022).
[31]
Drug interactions, cytochromes P450 and P-glycoprotein. 2020. Available From: https://www.hug.ch/sites/hde/files/structures/pharmacologie_et_toxicologie_cliniques/images/carte_des_cytochromes_2020.pdf
[32]
Flockhart, D.A.; Thacker, D.; McDonald, C.; Desta, Z. The flockhart cytochrome P450 drug-drug interaction table. 2021. Available From: https://drug-interactions.medicine.iu.edu/ accessed February 17, 2022
[33]
DDI-Predictor. Available from: www.ddi-predictor.org (accessed February 7, 2022)
[34]
Micromedex®. (electronic version). IBM Watson Health. 2022. Available from: https://www.micromedexsolutions.com/home/dispatch (accessed February 17, 2022)
[35]
Preston, L.C. Stockley’s drug interactions, 12th ed; Pharmaceutical Press: London, 2019.
[36]
Muniyan, S.; Rachagani, S.; Parte, S.; Halder, S.; Seshacharyulu, P.; Kshirsagar, P. Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling. Clin. Cancer Res., 2020.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-1569]
[37]
Das, A.; Durrant, D.; Mitchell, C.; Dent, P.; Batra, S.K.; Kukreja, R.C. Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. Oncotarget, 2016, 7(4), 4399-4413.
[http://dx.doi.org/10.18632/oncotarget.6749] [PMID: 26716643]
[38]
Greish, K.; Fateel, M.; Abdelghany, S.; Rachel, N.; Alimoradi, H.; Bakhiet, M.; Alsaie, A. Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer. J. Drug Target., 2018, 26(7), 610-615.
[http://dx.doi.org/10.1080/1061186X.2017.1405427] [PMID: 29148852]
[39]
Booth, L.; Roberts, J.L.; Poklepovic, A.; Gordon, S.; Dent, P. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget, 2017, 8(1), 1449-1468.
[http://dx.doi.org/10.18632/oncotarget.13640] [PMID: 27903966]
[40]
Booth, L.; Roberts, J.L.; Poklepovic, A.; Dent, P. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget, 2017, 8(8), 13464-13475.
[http://dx.doi.org/10.18632/oncotarget.14562] [PMID: 28088782]
[41]
Domvri, K.; Zarogoulidis, K.; Ziogas, N.; Zarogoulidis, P.; Petanidis, S.; Porpodis, K.; Kioseoglou, E.; Hohenforst-Schmidt, W. Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer. J. Cancer, 2017, 8(18), 3648-3656.
[http://dx.doi.org/10.7150/jca.21783] [PMID: 29151951]
[42]
Tavallai, M.; Hamed, H.A.; Roberts, J.L.; Cruickshanks, N.; Chuckalovcak, J.; Poklepovic, A.; Booth, L.; Dent, P. Nexavar/Stivarga and viagra interact to kill tumor cells. J. Cell. Physiol., 2015, 230(9), 2281-2298.
[http://dx.doi.org/10.1002/jcp.24961] [PMID: 25704960]
[43]
Booth, L.; Roberts, J.L.; Tavallai, M.; Nourbakhsh, A.; Chuckalovcak, J.; Carter, J.; Poklepovic, A.; Dent, P. OSU‐03012 and viagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood-brain barrier: Implications for anti‐cancer therapies. J. Cell. Physiol., 2015, 230(8), 1982-1998.
[http://dx.doi.org/10.1002/jcp.24977] [PMID: 25736380]
[44]
Tar, M.T.; Friedman, J.M.; Draganski, A.; Davies, K.P. Topically delivered nitric oxide acts synergistically with an orally administered PDE5 inhibitor in eliciting an erectile response in a rat model of radical prostatectomy. Int. J. Impot. Res., 2021, 34(6), 573-580.
[http://dx.doi.org/10.1038/s41443-021-00451-6] [PMID: 34017115]
[45]
Goswami, S.K.; Gangadarappa, S.K.; Vishwanath, M.; Razdan, R.; Jamwal, R.; Bhadri, N.; Inamdar, M.N. Antioxidant potential and ability of phloroglucinol to decrease formation of advanced glycation end products increase efficacy of sildenafil in diabetes-induced sexual dysfunction of rats. Sex. Med., 2016, 4(2), e106-e114.
[http://dx.doi.org/10.1016/j.esxm.2015.12.002] [PMID: 26831914]
[46]
Martínez-Salamanca, J.I.; La Fuente, J.M.; Cardoso, J.; Fernández, A.; Cuevas, P.; Wright, H.M.; Angulo, J. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. J. Sex. Med., 2014, 11(5), 1182-1192.
[http://dx.doi.org/10.1111/jsm.12477] [PMID: 24877179]
[47]
Gammella, E.; Leuenberger, C.; Gassmann, M.; Ostergaard, L. Evidence of synergistic/additive effects of sildenafil and erythropoietin in enhancing survival and migration of hypoxic endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol., 2013, 304(4), L230-L239.
[http://dx.doi.org/10.1152/ajplung.00112.2012] [PMID: 23204066]
[48]
Zhang, R.; Wang, Y.; Pan, L.; Tian, H. N-Acetylcysteine potentiates the haemodynamic-improving effect of sildenafil in a rabbit model of acute pulmonary thromboembolism via the p38 MAPK pathway. Clin. Exp. Pharmacol. Physiol., 2019, 46(2), 163-172.
[http://dx.doi.org/10.1111/1440-1681.13039] [PMID: 30289994]
[49]
Castro, M.M.; Rizzi, E.; Rascado, R.R.; Nagassaki, S.; Bendhack, L.M.; Tanus-Santos, J.E. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur. J. Pharmacol., 2004, 498(1-3), 189-194.
[http://dx.doi.org/10.1016/j.ejphar.2004.07.051] [PMID: 15363994]
[50]
Socała, K.; Nieoczym, D.; Wyska, E.; Poleszak, E.; Wlaź, P. Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 38(2), 121-126.
[http://dx.doi.org/10.1016/j.pnpbp.2012.02.013] [PMID: 22406168]
[51]
Dadkhah, F.; Safarinejad, M.R.; Asgari, M.A.; Hosseini, S.Y.; Lashay, A.; Amini, E. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int. J. Impot. Res., 2010, 22(1), 51-60.
[http://dx.doi.org/10.1038/ijir.2009.48] [PMID: 19865092]
[52]
Rochira, V.; Balestrieri, A.; Madeo, B.; Granata, A.R.; Carani, C. Sildenafil improves sleep-related erections in hypogonadal men: Evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J. Androl., 2006, 27(2), 165-175.
[http://dx.doi.org/10.2164/jandrol.05077] [PMID: 16278367]
[53]
Gholamine, B.; Motevallian, M.; Shafiei, M.; Mahmoudian, M. Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: A randomized, controlled study. J. Pharm. Pharm. Sci., 2008, 11(1), 22-31.
[http://dx.doi.org/10.18433/J3TG6H] [PMID: 18445362]
[54]
Blaise, S.; Hellmann, M.; Roustit, M.; Isnard, S.; Cracowski, J.L. Oral sildenafil increases skin hyperaemia induced by iontophoresis of sodium nitroprusside in healthy volunteers. Br. J. Pharmacol., 2010, 160(5), 1128-1134.
[http://dx.doi.org/10.1111/j.1476-5381.2010.00778.x] [PMID: 20590606]
[55]
Stocker, C.; Penny, D.J.; Brizard, C.P.; Cochrane, A.D.; Soto, R.; Shekerdemian, L.S. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med., 2003, 29(11), 1996-2003.
[http://dx.doi.org/10.1007/s00134-003-2016-4] [PMID: 14530859]
[56]
Ghofrani, H.A.; Wiedemann, R.; Rose, F.; Olschewski, H.; Schermuly, R.T.; Weissmann, N.; Seeger, W.; Grimminger, F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med., 2002, 136(7), 515-522.
[http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00008] [PMID: 11926786]
[57]
Zusman, R.M.; Prisant, L.M.; Brown, M.J. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J. Hypertens., 2000, 18(12), 1865-1869.
[http://dx.doi.org/10.1097/00004872-200018120-00022] [PMID: 11132612]
[58]
Hsiao, H-L.; Langenickel, T.H.; Petruck, J.; Kode, K.; Ayalasomayajula, S.; Schuehly, U.; Greeley, M.; Pal, P.; Zhou, W.; Prescott, M.F.; Sunkara, G.; Rajman, I. Evaluation of pharmacokinetic and pharmacodynamic drug-drug interaction of sacubitril/valsartan (lcz696) and sildenafil in patients with mild-to-moderate hypertension. Clin. Pharmacol. Ther., 2018, 103(3), 468-476.
[http://dx.doi.org/10.1002/cpt.759] [PMID: 28599060]
[59]
Oliver, J.J.; Kerr, D.M.; Webb, D.J. Time-dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate. Br. J. Clin. Pharmacol., 2009, 67(4), 403-412.
[http://dx.doi.org/10.1111/j.1365-2125.2009.03375.x] [PMID: 19371313]
[60]
Webb, D.J.; Muirhead, G.J.; Wulff, M.; Sutton, J.A.; Levi, R.; Dinsmore, W.W. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J. Am. Coll. Cardiol., 2000, 36(1), 25-31.
[http://dx.doi.org/10.1016/S0735-1097(00)00705-1] [PMID: 10898408]
[61]
Webb, D.J.; Freestone, S.; Allen, M.J.; Muirhead, G.J. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol., 1999, 83(5), 21-28.
[http://dx.doi.org/10.1016/S0002-9149(99)00044-2] [PMID: 10078539]
[62]
Parker, J.D.; Bart, B.A.; Webb, D.J.; Koren, M.J.; Siegel, R.L.; Wang, H.; Malhotra, B.; Jen, F.; Glue, P. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Crit. Care Med., 2007, 35(8), 1863-1868.
[http://dx.doi.org/10.1097/01.CCM.0000269371.70738.30] [PMID: 17522570]
[63]
Dalan, R.; Leow, M.K.S.; George, J.; Chian, K.Y.; Tan, A.; Han, H.W.; Cheow, S.P. Neuroglycopenia and adrenergic responses to hypoglycaemia: insights from a local epidemic of serendipitous massive overdose of glibenclamide. Diabet. Med., 2009, 26(1), 105-109.
[http://dx.doi.org/10.1111/j.1464-5491.2008.02634.x] [PMID: 19125771]
[64]
Socała, K.; Nieoczym, D.; Wyska, E.; Poleszak, E.; Wlaź, P. Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice. Pharmacol. Rep., 2012, 64(5), 1259-1266.
[http://dx.doi.org/10.1016/S1734-1140(12)70922-2] [PMID: 23238482]
[65]
Patrizi, R.; Leonardo, F.; Pelliccia, F.; Chierchia, S.L.; Galetta, P.; Cerquetani, E.; Frascà, F.; Fini, M.; Rosano, G.M. Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. Ital. Heart J., 2001, 2(11), 841-844.
[PMID: 11770869]
[66]
MacDiarmid, S.A.; Hill, L.A.; Volinn, W.; Hoel, G. Lack of pharmacodynamic interaction of silodosin, a highly selective α1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology, 2010, 75(3), 520-525.
[http://dx.doi.org/10.1016/j.urology.2009.10.042] [PMID: 20080287]
[67]
Sharifi, S.H.H.; Mokarrar, M.H.; Khaledi, F.; Yamini-Sharif, R.; Lashay, A.; Soltani, M.H. Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention? Int. Braz J Urol, 2014, 40(3), 373-378.
[http://dx.doi.org/10.1590/S1677-5538.IBJU.2014.03.11] [PMID: 25010303]
[68]
Leslie, S.; Atkins, G.; Oliver, J.; Webb, D. No adverse hemodynamic interaction between sildenafil and red wine. Clin. Pharmacol. Ther., 2004, 76(4), 365-370.
[http://dx.doi.org/10.1016/j.clpt.2004.07.005] [PMID: 15470336]
[69]
Weiss, J.; Theile, D.; Spalwisz, A.; Burhenne, J.; Riedel, K.D.; Haefeli, W.E. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem. Pharmacol., 2013, 85(2), 265-273.
[http://dx.doi.org/10.1016/j.bcp.2012.11.020] [PMID: 23219525]
[70]
Margelidon-Cozzolino, V.; Hodin, S.; Jacqueroux, E.; Delézay, O.; Bertoletti, L.; Delavenne, X. In vitro assessment of pharmacokinetic drug-drug interactions of direct oral anticoagulants: Type 5-phosphodiesterase inhibitors are inhibitors of rivaroxaban and apixaban efflux by p-glycoprotein. J. Pharmacol. Exp. Ther., 2018, 365(3), 519-525.
[http://dx.doi.org/10.1124/jpet.117.245993] [PMID: 29572341]
[71]
Mallah, E.M.; Rayyan, W.S.A.; Dayyih, W.A.A.; Elhajji, F.D.; Mansour, K.A.; Al-Majali, I.S. Dose-dependent synergistic effect of pomegranate juice on the bioavilability of sildenafil in rats by using HPLC method. Lat. Am. J. Pharm., 2016, 35, 1277-1284.
[72]
Al-Mohizea, A.M.; Ahad, A.; El-Maghraby, G.M.; Al-Jenoobi, F.I.; AlKharfy, K.M.; Al-Suwayeh, S.A. Effects of Nigella sativa, Lepidium sativum and Trigonella foenum-graecum on sildenafil disposition in beagle dogs. Eur. J. Drug Metab. Pharmacokinet., 2015, 40(2), 219-224.
[http://dx.doi.org/10.1007/s13318-014-0199-4] [PMID: 24719213]
[73]
Mekjaruskul, C.; Sripanidkulchai, B. Pharmacokinetic interaction between Kaempferia parviflora extract and sildenafil in rats. J. Nat. Med., 2015, 69(2), 224-231.
[http://dx.doi.org/10.1007/s11418-014-0882-4] [PMID: 25567192]
[74]
Hsueh, T.; Wu, Y.T.; Lin, L.C.; Chiu, A.; Lin, C.H.; Tsai, T.H. Herb-drug interaction of Epimedium sagittatum (Sieb. et Zucc.) maxim extract on the pharmacokinetics of sildenafil in rats. Molecules, 2013, 18(6), 7323-7335.
[http://dx.doi.org/10.3390/molecules18067323] [PMID: 23792897]
[75]
Tripathi, A.; Mazumder, P.; Chandewar, A. Evaluation of drug interaction of glimepiride with phosphodiesterase inhibitors type V in diabetic nephropathy. Exp. Clin. Endocrinol. Diabetes, 2014, 122(10), 597-601.
[http://dx.doi.org/10.1055/s-0034-1382034] [PMID: 25003363]
[76]
Miyakawa, S.; Tanaka, S.; Goto, T.; Uchida, S.; Takeuchi, K.; Inui, N.; Yamada, H.; Namiki, N.; Watanabe, H. Short-term drug interaction of bosentan and sildenafil under the long-term use in patients with pulmonary arterial hypertension. Life Sci., 2013, 93(25-26), e45.
[http://dx.doi.org/10.1016/j.lfs.2013.12.156]
[77]
Burgess, G.; Hoogkamer, H.; Collings, L.; Dingemanse, J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol., 2008, 64(1), 43-50.
[http://dx.doi.org/10.1007/s00228-007-0408-z] [PMID: 18040672]
[78]
Armstrong, D.W., III; Negro-Vilar, R.C.; Di Marino, M.E.; Staub, T.; Wargin, W.; Sullivan, E.J. A phase 1, single-center, open-label, drug interaction study to evaluate the pharmacokinetics, safety, and tolerability of co-administered BPS-MR and sildenafil at steady-state. Healthy Subjects. D33 Pulm. Hypertens. Treat; American Thoracic Society, 2011, pp. A5901-A5901.
[http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A5901]
[79]
Renard, D.; Bouillon, T.; Zhou, P.; Flesch, G.; Quinn, D. Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. Br. J. Clin. Pharmacol., 2015, 80(1), 75-85.
[http://dx.doi.org/10.1111/bcp.12584] [PMID: 25581063]
[80]
Stavros, F.; Kramer, W.G.; Wilkins, M.R. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br. J. Clin. Pharmacol., 2010, 69(1), 23-26.
[http://dx.doi.org/10.1111/j.1365-2125.2009.03541.x] [PMID: 20078609]
[81]
Al-Ghazawi, M.A.; Tutunji, M.S.; AbuRuz, S.M. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur. J. Clin. Pharmacol., 2010, 66(2), 159-163.
[http://dx.doi.org/10.1007/s00228-009-0738-0] [PMID: 19830413]
[82]
Jetter, A.; Kinzig-Schippers, M.; Walchner-Bonjean, M.; Hering, U.; Bulitta, J.; Schreiner, P.; Sörgel, F.; Fuhr, U. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin. Pharmacol. Ther., 2002, 71(1), 21-29.
[http://dx.doi.org/10.1067/mcp.2002.121236] [PMID: 11823754]
[83]
Abdelkawy, K.S.; Donia, A.M.; Turner, R.B.; Elbarbry, F. Effects of lemon and seville orange juices on the pharmacokinetic properties of sildenafil in healthy subjects. Drugs R D., 2016, 16(3), 271-278.
[http://dx.doi.org/10.1007/s40268-016-0140-1] [PMID: 27550653]
[84]
Hesse, C.; Siedler, H.; Burhenne, J.; Riedel, K.D.; Haefeli, W.E. Fluvoxamine affects sildenafil kinetics and dynamics. J. Clin. Psychopharmacol., 2005, 25(6), 589-592.
[http://dx.doi.org/10.1097/01.jcp.0000186866.82665.29] [PMID: 16282844]
[85]
Muirhead, G.J.; Wulff, M.B.; Fielding, A.; Kleinermans, D.; Buss, N. Pharmacokinetic interactions between sildenafil and saquinavir/] ritonavir. Br. J. Clin. Pharmacol., 2000, 50(2), 99-107.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00245.x] [PMID: 10930961]
[86]
Sekar, V.; Lefebvre, E.; De Marez, T.; De Pauw, M.; De Paepe, E.; Vangeneugden, T.; Hoetelmans, R.M.W. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin. Drug Investig., 2008, 28(8), 479-485.
[http://dx.doi.org/10.2165/00044011-200828080-00002] [PMID: 18598093]
[87]
Gotzkowsky, S.K.; Kumar, P.; Mottola, D.; Laliberte, K. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers. J. Cardiovasc. Pharmacol., 2013, 61(5), 444-451.
[http://dx.doi.org/10.1097/FJC.0b013e3182893d90] [PMID: 23429588]
[88]
Spence, R.; Mandagere, A.; Dufton, C.; Venitz, J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J. Clin. Pharmacol., 2008, 48(12), 1451-1459.
[http://dx.doi.org/10.1177/0091270008324180] [PMID: 18832294]
[89]
Sidharta, P.N.; van Giersbergen, P.L.M.; Wolzt, M.; Dingemanse, J. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects. Br. J. Clin. Pharmacol., 2014, 78(5), 1035-1042.
[http://dx.doi.org/10.1111/bcp.12447] [PMID: 24962473]
[90]
VanWert, A.L.; McCune, D.F.; Brown, K.M.; Bommareddy, A.; Manning, D.H.; Roman, C.L. Sodium Oxybate for Narcolepsy. J. Pharm. Technol., 2014, 30(6), 240-243.
[http://dx.doi.org/10.1177/8755122514545518] [PMID: 34860897]
[91]
Pross, N.; Patat, A.; Vivet, P.; Bidaut, M.; Fauchoux, N. Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers. Br. J. Clin. Pharmacol., 2015, 80(3), 480-492.
[http://dx.doi.org/10.1111/bcp.12632] [PMID: 25782469]
[92]
Thai, D.; Dyer, J.E.; Benowitz, N.L.; Haller, C.A. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J. Clin. Psychopharmacol., 2006, 26(5), 524-529.
[http://dx.doi.org/10.1097/01.jcp.0000237944.57893.28] [PMID: 16974199]
[93]
Eller, M.; Halladay, W.; Madrid, A. Evaluation of drug-drug interactions of sodium oxybate: Results from pharmacokinetic/pharmacodynamic studies with duloxetine, lorazepam, and tramadol. Arthritis Rheum., 2010, 62(10)
[94]
Eller, M.; Skowronski, R.; Wesnes, K.; Alvarez-Horine, S.; Benson, B.; Black, J. Evaluation of drug-drug interactions of sodium oxybate with diclofenac: Results from a pharmacokinetic/pharmacodynamic study. Sleep Med., 2013, 14, e115.
[http://dx.doi.org/10.1016/j.sleep.2013.11.253]
[95]
Rodriguez-Cruz, V.; Ren, T.; Morris, M.E. Drug‐drug interaction between diclofenac and gamma‐hydroxybutyric acid. Biopharm. Drug Dispos., 2021, 42(8), 351-358.
[http://dx.doi.org/10.1002/bdd.2296] [PMID: 34191301]
[96]
Haller, C.; Thai, D.; Jacob, P., III; Dyer, J.E. GHB urine concentrations after single-dose administration in humans. J. Anal. Toxicol., 2006, 30(6), 360-364.
[http://dx.doi.org/10.1093/jat/30.6.360] [PMID: 16872565]
[97]
Eller, M.; Wang, Y.; Wesnes, K.; Alvarez-Horine, S.; Benson, B.; Black, J. Evaluation of drug-drug interactions of sodium oxybate with divalproex: Results from a pharmacokinetic/pharmacodynamic study. Sleep Med., 2013, 14, e302-e303.
[http://dx.doi.org/10.1016/j.sleep.2013.11.741]
[98]
Vijay, N.; Morris, M.E. Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid. J. Pharm. Sci., 2014, 103(10), 3310-3315.
[http://dx.doi.org/10.1002/jps.24122] [PMID: 25174723]
[99]
López-Arnau, R.; Buenrostro-Jáuregui, M.; Muñoz-Villegas, P.; Rodríguez-Morató, J.; Ciudad-Roberts, A.; Duart, L.; Camarasa, J.; De la Torre, R.; Pubill, D.; Escubedo, E. The combination of MDPV and ethanol results in decreased cathinone and increased alcohol levels. Study of such pharmacological interaction. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2017, 76, 19-28.
[http://dx.doi.org/10.1016/j.pnpbp.2017.02.011] [PMID: 28219712]
[100]
Bedada, W.; de Andrés, F.; Engidawork, E.; Pohanka, A.; Beck, O.; Bertilsson, L.; Llerena, A.; Aklillu, E. The psychostimulant khat (Catha edulis) inhibits CYP2D6 enzyme activity in humans. J. Clin. Psychopharmacol., 2015, 35(6), 694-699.
[http://dx.doi.org/10.1097/JCP.0000000000000413] [PMID: 26444948]
[101]
Drevin, G.; Rossi, L.H.; Férec, S.; Briet, M.; Abbara, C. Chemsex/slamsex-related intoxications: A case report involving gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature. Forensic Sci. Int., 2021, 321, 110743.
[http://dx.doi.org/10.1016/j.forsciint.2021.110743] [PMID: 33640780]
[102]
Néfau, T; Martinez, M; Detrez, V. Le Point SINTES numéro 5.Paris: Observatoire français des drogues et des toxicomanies. 2019. Available from: https://www.ofdt.fr/BDD/sintes/LePointSINTES05. pdf (accessed February 17, 2022)
[103]
Mounteney, J.; Bo, A.; Oteo, A. European monitoring centre for drugs and drug addiction. The internet and drug markets; Publications Office of the European Union: Luxembourg, 2016. Available from: https://www.emcdda.europa.eu/publications/insights/internet-drug-markets_en (accessed February 17, 2022)
[104]
Jouanjus, E.; Lapeyre-Mestre, M.; Micallef, J. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J. Am. Heart Assoc., 2014, 3(2), e000638.
[http://dx.doi.org/10.1161/JAHA.113.000638] [PMID: 24760961]
[105]
Marillier, M.; Batisse, A.; Richeval, C.; Labrouve, V.; Martinez, M.; Allorge, D.; Gregoire, M.; Batel, P.; Nefau, T.; Chevallier, C.; Gaulier, J-M.; Djezzar, S. CHEMSEX, NPS & risk reduction management: Preliminary results of a pilot study. Toxicol. Anal. Clin., 2017, 29(1), 47-56.
[http://dx.doi.org/10.1016/j.toxac.2016.12.003]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy